Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Competing Interests: The authors declared no competing interests. Monogenic hypertension is caused by single gene mutations and accounts for a spectrum of familial forms of elevated blood pressure ...

Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

ABSTRACT: The research project aims to perform genetic profiling in Bulgarian patients with latent or active tuberculosis (TB) and assess the influence of genetic polymorphisms on disease ...

The company’s technology also benefitted from $401m in Series D financing in June 2023. ElevateBio’s CEO David Hallal said: ...

Despite insufficient evidence to support direct-to-consumer genetic testing in routine clinical care, cardiovascular ...

单基因糖尿病（Monogenic diabetes）是由单个基因或染色体位点的一个或多个缺陷引起。该疾病可能在家族内作为显性、隐性或非孟德尔性状遗传，但也可能由于新发突变而自发出现。

DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...